Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor
Edgar G. Fischer, Matthias Riewald, Hui-Yu Huang, Yohei Miyagi, Yoshinobu Kubota, Barbara M. Mueller, Wolfram Ruf
Edgar G. Fischer, Matthias Riewald, Hui-Yu Huang, Yohei Miyagi, Yoshinobu Kubota, Barbara M. Mueller, Wolfram Ruf
View: Text | PDF
Article

Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor

  • Text
  • PDF
Abstract

Tissue factor (TF), the cell-surface receptor for coagulation factor VIIa, supports metastasis. Equally important for this process are (a) interactions of the TF cytoplasmic domain, which binds the mobility-enhancing actin-binding protein 280, and (b) the formation of a proteolytically active TF-VIIa complex on the tumor cell surface. In primary bladder carcinoma cells, we find that this complex localizes to the invasive edge, in proximity to tumor-infiltrating vessels that stain intensely for TF pathway inhibitor (TFPI-1), the major inhibitor of the protease activity of the complex. In culture, binding of VIIa to TF-expressing tumor cells is sufficient to allow cell adhesion, migration, and intracellular signaling on immobilized TFPI-1. Immobilized heparin, a mimic for extracellular matrix–associated proteoglycans, binds physiological concentrations of TFPI-1 in a conformation that supports TF-VIIa–dependent cell adhesion. Consistent with a functional role of TFPI-1 in complex extracellular matrices, we show that TF cooperates with integrin-mediated adhesion and migration on composite matrices that contain ligands for both integrins and the TF-VIIa complex. This study thus provides evidence for a novel mechanism of protease-supported migration that is independent of proteolytic matrix degradation but rather involves protease-dependent bridging of TF’s extracellular domain to an ECM-associated inhibitor.

Authors

Edgar G. Fischer, Matthias Riewald, Hui-Yu Huang, Yohei Miyagi, Yoshinobu Kubota, Barbara M. Mueller, Wolfram Ruf

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
(a) J82 bladder carcinoma cell adhesion to (top) and migration toward (b...
(a) J82 bladder carcinoma cell adhesion to (top) and migration toward (bottom) the indicated matrices (control [BSA],10 μg/mL fibronectin [FN], 50 μg/mL antibody TF9-6B4 [anti-TF], 100 μg/mL recombinant TFPI-1 [TFPI]) in the presence of 10 nM (adhesion) or 50 nM (migration) recombinant VIIa (VIIa), VIIa covalently active site modified with Phe-Phe-Arg chloromethylketone (FFR-VIIa), VIIa rendered catalytically inactive by catalytic triad Ser 344→Ala mutation (VIIa Ala 344), or factor Xa (Xa). A total of 5 U/mL of heparin was included in all experiments to block proteoglycan-dependent attachment. (b) Phosphorylation of focal adhesion kinase (FAK) in response to adhesion to TFPI-1. Wells were coated with 10 μg/mL poly-L-lysine (PL) or the indicated proteins at concentrations as described for a. Cells were allowed to adhere for 30 minutes in the presence of 5 U/mL heparin where indicated (+), and with the indicated soluble proteins at 10 nM. The top panel shows an anti-phosphotyrosine (anti-PY), and the bottom panel shows an anti-FAK blot of whole-cell lysates.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts